Platelets (PLT) >= 100,000/mcL
36.0
Platelets >= 100,000/mcL
102.0
Platelets >= 100,000/mcl
360.0
Platelets >= 100,000/mcL
276.0
Platelets >= 100,000/mcl
162.0
Platelets >= 100,000/mcL
40.0
Platelets >= 100,000/mcL
107.0
Platelets >= 100,000/mcl
52.0
Platelets >= 100,000/mcL
55.0
Platelets >= 100,000/mcL
165.0
Platelets >= 100,000/mcL
42.0
Platelets >= 100,000/mcL
36.0
Platelets >= 100,000/mcL
140.0
Platelets >= 100,000/mcL
80.0
Platelets >= 100,000/mcL
68.0
Platelets >= 75,000/mcL
42.0
Platelets >= 100,000/mcL
73.0
Platelets >= 100,000/mcL
80.0
Platelets >= 100,000/mcL
70.0
Platelets >= 100,000/mcL
72.0
Platelets >= 100,000/mcL (without transfusion)
12.0
Platelets >= 100,000/mcL
68.0
Platelets greater than or equal to 100,000/mcl
540.0
Platelets >= 50,000/mcL
54.0
Platelets >= 100,000/mcL
32.0
Platelets >= 100,000/mcL
100.0
Platelets >= 100,000/mcL
24.0
Platelets >= 100,000/mcL
35.0
Platelets >= 100,000/mcL
230.0
Platelets >= 100,000/mcL
40.0
Platelets >= 100,000/mcL
57.0
Platelets >= 50,000 cells/mcL (50 x 10^9/L)
52.0
Platelets >= 100,000/mcL
90.0
Platelets >= 100,000/mcL
36.0
Platelets >= 100,000/mcL
23.0
Platelets >= 50,000/mcL or recovery to the baseline count
80.0
Platelets >= 75,000/mcL
135.0
Platelets >= 100,000/mcL
37.0
Platelets >= 150,000/mcL
66.0
Platelets >= 50,000/mcL
12.0
Platelets >= 100,000/mcL
42.0
Platelets >= 100,000/mcL
209.0
Platelets >= 100,000/mcL
30.0
Platelets >= 100,000/mcL
75.0
Platelets >= 100,000/mcL (not requiring platelet transfusions)
50.0
Platelets >= 100,000/mcL
30.0
Platelets >= 100,000/mcL
549.0
Platelets >= 100,000/mcL
680.0
Platelets >= 100,000/mcL
46.0
Platelets >= 100,000/mcL
45.0
Platelets >= 100,000/mcL
82.0
Platelets >= 100,000/mcL
126.0
Platelets >= 100,000/mcL
150.0
Platelets >= 100,000/mcL
50.0
Platelets >= 75,000/mcL
46.0
Platelets >= 100,000/mcL
15.0
Platelets >= 100,000/mcL
46.0
Platelets >= 50,000/mcL
36.0
Platelets >= 100,000/mcL
90.0
Platelets >= 100,000/mcL
45.0
Platelets >= 75,000/mcL, unless due to marrow involvement by lymphoma in which case a platelet count of >= 30,000/mcL will be used
50.0
Platelets >= 100,000/mcL
46.0
Platelets > 50,000/mcL
60.0
Within 2 weeks prior to initiation of study treatment: Platelets >= 100,000/mcL
70.0
Platelets >= 100,000/mcL (without transfusion within 2 weeks prior to cycle 1, day 1)
29.0
Platelets >= 100,000/mcL
51.0
Platelets >= 100,000/mcL
150.0
Platelets >= 100,000/mcL
48.0
Platelets >= 100,000/mcL
20.0
Platelets >= 75,000/mcl
84.0
Platelets >= 100,000/mcL
60.0
Platelets >= 100,000/mcL
38.0
Platelets >= 100,000/mcL
70.0
Platelets >= 100,000/mcL
24.0
Platelets >= 100,000/mcL
35.0
Platelets >= 100,000/mcL (not requiring platelet transfusions)
24.0
Platelets >= 100,000/mcL
28.0
Platelets >= 100,000/mcL
148.0
Platelets >= 100,000/mcL
72.0
Platelets >= 75,000/mcL (>= 50,000 for patients with hematologic malignancies)
40.0
Platelets >= 150,000/mcL
60.0
Platelets >= 100,000/mcL
180.0
Platelets >= 100,000/mcL
40.0
Platelets >= 100,000/mcL
22.0
Platelets >= 100,000/mcL
70.0
Platelets >= 100,000/mcL
47.0
Platelets >= 100,000/mcL
35.0
Platelets >= 100,000/mcL
78.0
Platelet count: >= 50,000/mm^3, transfusion independent (no platelet transfusions within 1 week)
62.0
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
77.0
For patients with solid tumors without known bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
154.0
Platelets >= 100,000/mm^3 transfusion independent (no platelet transfusion one week prior to enrollment)
40.0
Platelet count >= 75,000 and transfusion independent
28.0
For patients with solid tumors without known bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
148.0
Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
484.0
* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
81.0
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
67.0
For patients with solid tumors without known bone marrow involvement: * Peripheral absolute neutrophil count (ANC) >= 1000/mm^3* Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)* Hemoglobin >= 8.0 g/dl at baseline (may receive packed red blood cell [PRBC] transfusions)
65.0
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
36.0
Platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) for patients with solid tumors without bone marrow involvement
146.0
For patients with solid tumors without known bone marrow involvement:* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)* Hemoglobin >= 8.0 g/dl at baseline (may receive red blood cell [RBC] transfusions)
51.0
For patients with solid tumors without known bone marrow involvement:* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
49.0
For patients with solid tumors without known bone marrow involvement:* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
98.0
For patients with solid tumors without known bone marrow involvement:* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
49.0
For patients with solid tumors without known bone marrow involvement:* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
49.0
For patients with solid tumors without known bone marrow involvement:* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
144.0
For patients with solid tumors without known bone marrow involvement:* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 within 7 days prior to enrollment * Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
49.0
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: For patients with solid tumors without known bone marrow involvement:* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment
1500.0
Platelet count >= 100,000/ul
729.0
Platelet count > 75,000/uL
253.0
Platelet count >= 100,000/uL
100.0
Platelet count >= 100,000/uL
74.0
Platelet count >= 100,000/uL (transfusion independent)
275.0
Platelet count >= 75,000/uL (transfusion independent)
74.0
CD4 count >= 50 cells/ul
70.0
Platelet count >= 100,000/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
340.0
Platelet count >= 100,000/uL, obtained within 4 weeks prior to randomization
300.0
Platelet count >= 100,000/uL
400.0
Platelets >= 75,000 cells /uL (unsupported, defined as no platelet transfusion within 7 days)
110.0
INCLUSION CRITERIA FOR STRATUM C: Platelets >= 75,000 cells/uL (unsupported, defined as no platelet transfusion within 7 days)
110.0
Platelet count >= 50,000/uL
44.0
Absolute CD4 count > 200 cells/uL
46.0
Platelet count >= 75,000/uL
337.0
CD4+ T-cell count >= 100 cells/uL
60.0
Platelet count >= 100,000/uL (transfusion independent)
45.0
Platelets >= 100,000/uL (untransfused)
400.0
Platelets >= 100,000 cells/uL (75 x 10^9 L); and,
90.0
Platelets >= 100,000/ul
97.0
Platelets >= 100,000/uL
72.0
Platelets >= 100,000/ul
104.0
TUMOR BIOPSY SEQUENCING: Platelets >= 100,000/uL (mcL)
700.0
TREATMENT: Platelets >= 100,000/uL (mcL)
700.0
Platelets >= 100,000/ul (unsupported)
52.0
Platelets >= 90 x 10^3/uL
92.0
Platelets >= 100,000/uL
23.0
Platelets >= 100,000/ul
280.0
Platelets >= 100,000/ul
450.0
Platelets >= 100,000/ul
96.0
Platelets >= 100,000/uL
58.0
Platelets >= 100,000/uL
35.0
Platelets > 100,000/uL
188.0
Platelets >= 100,000/uL
33.0
Platelets > 100,000/uL
32.0
Platelets >= 100 x 10^3/uL
714.0
Platelets >= 100,000/uL
40.0
Platelets >= 100,000/uL
30.0
Platelets >= 100,000/ul
50.0
Platelet count >= 100,000/mmï¿½
700.0
Platelet (PLTs) count >= 100,000/mm^3 obtained =< 21 days prior to registration
360.0
Platelet count >= 100,000 cells/mcL
155.0
Peripheral platelet count (PLT) >= 75,000/mm^3
48.0
Platelet count >= 100,000/mm^3
1120.0
Platelet count > 100,000
224.0
Platelet count >= 100,000/mL within 28 days prior to registration
1900.0
STEP I: Untransfused platelet count >= 75,000 cells/mm^3 (obtained within 28 days prior to randomization)
1080.0
Platelet count < 100 x 10^9/L
45.0
Platelet count > 100,000/mm^3
2060.0
Platelet count >= 50 x 10^9/L
97.0
Platelet count >= 75,000/mm^3 within 90 days prior to randomization
150.0
Platelet count >= 100,000/mm^3
34.0
Platelet count >= 100,000 mcl obtained within 28 days prior to sub-study registration
10000.0
Platelet count >= 100 x 10^9/L
250.0
Platelet count >= 100 x 10^9/L measured within 28 days prior to randomization
1500.0
Platelet count >= 100,000/mm^3
20.0
Platelet count >= 100,000/mcL
600.0
Patients on Part C with acute lymphoblastic leukemia: platelet count >= 20,000/mm^3 (may receive platelet transfusions); these patients must not be known to be refractory to red cell or platelet transfusion
148.0
Platelet count > 50,000/mm^3
125.0
Platelet count >= 75,000/mm^3
30.0
Platelet count >= 100,000/mm^3
420.0
Within 6 weeks prior to randomization: Platelet count must be >= 100,000/mm^3
990.0
Platelet count >= 100,000/mm^3
195.0
Re-registration: platelet count >= 100,000/mm^3
195.0
Within 14 days of registration: Platelet count >= 75,000/mm^3
110.0
Platelet count >= 100,000/mm^3
69.0
Platelet count >= 100,000/mm^3
130.0
Platelet count >= 100,000/mm^3
45.0
Platelet count >= 75,000/mcL; must be obtained within 28 days prior to registration
180.0
Platelet count >= 100,000/ mL within 21 days prior to registration
333.0
Platelet count >= 100,000/mm^3
137.0
CLINICAL/LABORATORY CRITERIA: Platelet count >= 100,000/mcL; these results must be obtained within 28 days prior to registration
53.0
Platelet count must be >= 100,000/mm^3 within 28 days before randomization
348.0
Platelet count >= 100,000/mm^3, within 4 weeks of randomization
766.0
Platelet count >= 100,000/mm^3
124.0
Platelet count >= 100,000 mm^3; platelets >= 75,000 required for patients who received cycle 1 of mFOLFOX6 prior to registration
700.0
Platelet count < 100 x 10^9/L
98.0
Platelet count >= 75,000/mm^3
324.0
Platelets >= 100,000 cells/mm^3
285.0
Platelets >= 100,000 cells/mm^3
37.0
Platelets >= 70,000 cells/mm^3, within 21 days prior to study entry
143.0
Platelets >= 60,000 cells/mm^3; obtained within 14 days prior to study entry
368.0
Platelets >= 100,000 cells/mm^3
252.0
Platelets >= 100,000 cells/mm^3
660.0
Platelets >= 100,000 cells/mm^3
234.0
Platelets >= 100,000 cells/mm^3 obtained within 30 days prior to registration
330.0
Platelets >= 100,000 cells/mm^3 within 14 days prior to study registration
440.0
Platelets >= 100,000 cells/mm^3, within 21 days prior to registration
924.0
Platelets >= 100,000 cells/mm^3
182.0
Platelets >= 100,000 cells/mm^3
606.0
Platelets >= 50,000 cells/mm^3
360.0
Platelets >= 50,000 cells/mm^3
186.0
Platelets >= 100,000 cells/mm^3
120.0
Platelets >= 100,000/mm^3, equivalent to CTCAE v 3.0 grade 0-1
164.0
Platelets >= 100,000/mm^3
545.0
Within 60 days prior to registration on study: Platelets >= 100,000/mm^3
2580.0
Platelets >= 100,000/mm^3
130.0
Platelets >= 100,000/mm^3
110.0
Platelets >= 100,000/mm^3
52.0
Platelets: >= 75,000/mm^3 within 90 days before enrollment
5058.0
Platelets >= 50,000 /mm^3
84.0
Platelets >= 100,000/mm^3
44.0
Platelets >= 30,000/mm^3
NONE
Platelets > 100,000 mm^3, must be obtained within 8 weeks prior to screening for protocol therapy
562.0
Platelets: >= 100,000/mm^3
56.0
Platelets >= 100,000/mm^3
60.0
Platelets >= 100,000/mm^3
126.0
Platelets >= 100,000/mm^3 within 4 weeks prior to randomization
345.0
Platelets >= 100,000/mm^3
36.0
Platelets >= 100,000/mm^3
24.0
Platelets: >= 100,000 / mm^3
56.0
Platelets >= 100,000 cell/mm^3
612.0
Platelets >= 100,000/mcL assessed within seven (7) days prior to the start of therapy
30.0
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Platelets >= 100,000/mcl
162.0
Obtained within 30 days of registration: Platelets >= 75,000/mcL or >= 50,000/mcL with documented bone marrow involvement
24.0
Platelets >= 100,000/mcL within 28 days prior to registration
491.0
Obtained =< 7 days prior to registration: Platelets (PLT) >= 100,000/mm^3
102.0
Platelets >= 100,000/L (unsupported), within 14 days of registration and within 7 days of the start of treatment
180.0
Platelets >= 75,000/mcL (75 x 10^9/L) obtained within 2 weeks prior to registration
189.0
Platelets >= 50,000/mcl within 28 days prior to registration
44.0
Registration Step 3 ï¿½ Maintenance: Patients must have adequate marrow function as evidenced by platelets >= 75,000/mcl within 28 days prior to registration
44.0
Obtained within 28 days prior to registration: Platelets >= 75,000/mcL
223.0
Within 14 days prior to registration: Platelets >= 100,000/mcL
143.0
Platelets greater than or equal to 100,000/mcl, within 14 days prior to registration
147.0
Obtained within 28 days prior to registration: Platelets >= 50,000/mcl
77.0
Platelets >= 100 x 10^9/L within 14 days prior to registration.
186.0
Within 28 days prior to registration: Platelets >= 75,000/mcL
707.0
Within 14 days prior to registration: Platelets >= 100,000/mcl
488.0
Within 28 days prior to administration of study treatment: Platelets >= 100,000/mcL
90.0
Within less than or equal to 14 days prior to registration: Platelets >= 100 x 10^9/L
40.0
Within 28 days prior to administration of therapy: Platelets >= 100,000/mcL
132.0
Platelets >= 100,000/mcL, obtained within 28 days prior to step 2 registration
1000.0
Platelets >= 100,000/mcL within 28 days prior to registration
64.0
Platelets >= 75,000/mcL within 28 days prior to registration
150.0
Platelets >= 100,000/mcL within 28 days prior to registration
94.0
Platelets >= 100 x 10^9/L
72.0
Platelets >= 100 x 10^9/L
30.0
Platelets >= 100 x 10^9/L
40.0
Platelets >= 100 x 10^9/L, within 2 weeks of the first dose of study treatment
18.0
Platelets >= 75 x 10^9/L
68.0
Platelets >= 100 x 10^9/L
130.0
Platelets >= 100 x 10^9/L
35.0
Platelets >= 100 x 10^9/L
18.0
Platelets (Plt) > 100
23.0
Platelets >= 100,000/microliters
37.0
Platelets >= 100 x 10^9/L
36.0
Platelets >= 100 x 10^9/L
64.0
Platelets >= 100 x 10^9/L (transfusion dependent)
25.0
Platelets >= 75 x 10^9/L
68.0
Platelets >= 100,000 x 10^9 /L
21.0
Platelets >= 75 x 10^9/L within 30 days of day 1 of study
27.0
